Discovery research and development history of the dopamine D 2 receptor partial agonists, aripiprazole and brexpiprazole

• Published in: Neuropsychopharmacology reports Vol. 41; no. 2; pp. 134 - 143
• Main Authors: Kikuchi, Tetsuro, Maeda, Kenji, Suzuki, Mikio, Hirose, Tsuyoshi, Futamura, Takashi, McQuade, Robert D.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.06.2021
• Subjects: Agonists; Antipsychotics; Aripiprazole - therapeutic use; Depressive Disorder, Major - drug therapy; Dopamine; Dopamine Agonists - therapeutic use; Drug dosages; Humans; Hypotheses; Psychotropic drugs; Quinolones; R&D; Research & development; Schizophrenia; Serotonin; Thiophenes; United States; United States; Canada; United States > US; Japan; Europe; aripiprazole; dopamine-system stabilizer; brexpiprazole; dopamine D2 receptor partial agonist; serotonin-dopamine activity modulator

Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D 2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify ® ). The drug was approved for this indication in the United States in 2002 and has received approval in the United States, Europ...